Ignite Creation Date:
2025-12-25 @ 12:45 AM
Ignite Modification Date:
2026-05-02 @ 6:04 PM
Study NCT ID:
NCT02993367
Status:
UNKNOWN
Last Update Posted:
2017-03-16
First Post:
2016-12-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND
Sponsor:
The Second Hospital of Hebei Medical University
Organization:
Study Overview
Official Title:
The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND:A Randomized, Double-blind,and Neuroimaging Study
Status:
UNKNOWN
Status Verified Date:
2017-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EBSCPVCIND
Brief Summary:
Vascular cognitive impairment no dementia (VCIND) is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it. VCIND caused by subcortical ischemic small vessel disease (hereinafter, subcortical VCIND) represents a relatively homogeneous disease process and is a suitable target for therapeutic trials investigating VCIND. Preclinical trials showed that Butylphthalide Soft Capsules is effective for cognitive impairment of vascular origin. In this randomized, double-blind, placebo-controlled trial, the investigators apply fMRI study the effects of Butylphthalide Soft Capsules in patients with VCIND.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: